BNP Paribas Financial Markets Grows Holdings in Accuray Incorporated (NASDAQ:ARAY)

BNP Paribas Financial Markets lifted its position in Accuray Incorporated (NASDAQ:ARAY) by 1,650.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 146,384 shares of the medical equipment provider’s stock after purchasing an additional 138,022 shares during the period. BNP Paribas Financial Markets owned about 0.15% of Accuray worth $263,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Nisa Investment Advisors LLC increased its stake in Accuray by 253,483.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 15,209 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Accuray in the second quarter worth about $30,000. US Bancorp DE grew its position in shares of Accuray by 1,087.7% during the third quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 16,316 shares in the last quarter. Caprock Group LLC bought a new stake in Accuray during the 3rd quarter valued at approximately $36,000. Finally, Intech Investment Management LLC purchased a new position in Accuray in the 3rd quarter worth approximately $41,000. 64.08% of the stock is currently owned by institutional investors.

Accuray Price Performance

Shares of Accuray stock opened at $1.95 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. Accuray Incorporated has a 12 month low of $1.40 and a 12 month high of $3.05. The stock has a 50 day moving average of $1.91 and a 200 day moving average of $1.88. The firm has a market cap of $196.10 million, a PE ratio of -11.47 and a beta of 1.44.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to analyst estimates of $98.10 million. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. During the same period last year, the firm posted ($0.03) earnings per share. On average, research analysts expect that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.